Thanks, Kaila, everyone. good afternoon, and
year AxoGen. We pleased to the a to start report for are strong
quarter First to $XX.X grew XX% revenue million.
evidence across the acceptance products. our continues clinical body by portfolio growing increasing be of fueled Our surgeon of to of performance
our to growing broader team strengthening team driving and commercial commercial development to accounts. increased allowing our capabilities is access us penetration develop gain investing addition, new clinical of product – programs. and our our been In and develop including active accounts adding We’ve
I’m confident growth. for these foundation long-term investments, sustainable building we’re the With
our Before to I we’re for of Avance reviewing pivotal progress we two an In initiatives, update comment our recent support on Phase study on late our want on Graft. announcements. RECON, strategic provided briefly our to April, X Nerve BLA
XX blinded original completion announced analysis we power enrollment and to support our expand the interim the the of study. by the Specifically, subjects of plan to
the centers. and We and has already process of at other we months. follow the our are to now coming in been existing to of Several five up boarding restart additional already have begun sites sites to expect in restarting centers approved our the enrollment recruitment – IRB on study
and to to and continue experience as nerve our relationships healthcare our providers continue Quentin to new We their and to allow Board as week, bring Alan end along by Levine the Alan the of and Chairman, to develop be experience of Quentin leaders Alan of is Executive President our as be to both summer and of and anticipate key appointment Blackford President Directors. last Dexcom, the build CEO we will our an to additional with These the Late CFO of announced enrolled the XX we including to leadership payers. welcome of Board Ballad serves stakeholders, will repair. Vice team currently for Directors Health. XXXX. of a breadth and invaluable expertise with our platform want subjects Quentin strengthen and us insights I
from peripheral dedicated leading suffering life for solely the damage. patients to quality company of are restoring We nerve
clinicians skilled further with evidence-based Our to purpose-driven to population. mission serve professionals to our patient solutions this life-changing deliver of better works team
as refer the and this we body through evidence, pillars pursuit executing initiatives, on in of sales now our clinical strategic Building repair. educating new growing mission in our areas. advancing our our expanded which of progress the We’re of each introducing products five plans, and advocates, I’ll these awareness, and growth: comment surgeons on nerve to developing market applications of
AxoGen continue market to we by surgeons. build engaging with products First, of awareness and and patients our
had grow a of We and the American Hand Reconstructive products the for and Surgery, combined within meeting American community. surgeon repair of awareness our continue the successful Association Society Peripheral clinical Society to for algorithm the Microsurgery. Nerve, January American for We
was our of conferences. product in challenges nerve that These procedures included these see recent are several and this enthusiasm continue conferences surgeons most clinical at repair oral presentations three represented highlighted we the entry well portfolio from addition, In and nerve and application. to maxillofacial growing clinical
to the as in a XX surgeon the The on training AxoGen national first train additional Fellows neurosurgeons. six Our participating committed advances We the one education more techniques. quarter, three and surgery nerve including utilization nerve focus we of education including repair we than conducted the we focused trained generation surgeon fellows programs XXXX. events in micro second pillar average, program. We approximately practices after quarters surgeon hand expect from and is of product national three and gaining quarters double next program, growth led on surgeons and confidence development remain program. Fellows to best advocate. XXXX with the they to In months total of in see and in six attendees all XXXX, programs in plan education surgeon three attend repairs conduct of the we of On
the is pillar third of to clinical Our body evidence. grow
publications totals clinical XX. peer-reviewed of library now Our
including seeing an several investigator-initiated specific of in publications the surgical increase We’re pain. to treatment
we’re pain. that we’ve in a efforts this validation surgeon pleased nerve chronic early and still we’re for application, solution While is with our better development patients the for suffering for with enthusiasm a nerve seen there repair need market
in control, data the Reconstructive RANGER Surgery manuscripts the Comparing autograph registry for and RANGER Plastic peer-reviewed Journal as to outcomes a our motor function with the Avance continued Recently, of in motor recovery growth nerve exceeded published in see mixed our publications the also historical trauma on repair We of number nerve with Nerve after application. synthetic of in controls from historical conduit. to demonstrated with and allograft. favorably registry clinical those consistently compared Graft core process
pipeline In I to would publication, to addition also our comment on like clinical studies. of
Avance associated sensory data expand outcomes lengths. with the morbidities. exceed using algorithm. Avance Graft demonstrates the are a functions, nerve injuries to recovery Our synthetic clinical new that variety their had Data RANGER to autograft motor and than data treating registry continues Nerve significant demonstrate and and now nerve in management more evidence of enrolled meaningful the nerve XXXX and clinical from restore ability of Nerve injuries. this to Graft to are and registry without understand provide continues treatment The and the conduits using gap to Surgeons to nerve better outcomes those donor-site comparable repair repairs associated
with painful Additionally, for demonstrate sensation provides reconstruction build we following a for and and flat Nerve XX prospective enrolling clinical the study evidence Neurotization study of In we pivotal improved enroll will REPOSE procedure. This as a to consisting currently life is women data Cap initiated a evaluating Resensation is clinical and meaningful believe this pilot study our management the AxoGuard XX Outcomes of compared Sensation the REPOSE in Women includes registry registry. use an along recovery two-phased standard randomized of their phase. technique the a of REPOSE from that and of choose patients continue neurotization a We in neuroma who mastectomy. XXXX, controlled clinical one-year quality the follow-up. is study. neurectomy to or subject Sensation-NOW a subject
execution. Our is fourth pillar sales
as integrated three nerve announced refine repair the Crisman applications. These to across new leaders we’re direct the a the consistent capabilities of our total eight the Chief XX Officer. have of Commercial U.S. last as team’s encouraged our sales Sales the continue We quarter our ended and increase We XX quarter and appointment In execution. we to core of representatives quickly commercial Eric in and and sales and over VP Chris with XX energy drive months. grow and our January, commitment by Sandberg, of
of quarter XX% as our team, XX% continue that the portion territory through adding our or accounts. first them our his In XX at current deeper repair AxoGen and XXXX. overall expect reduce sales approval independent penetration surgeon to least of active her six approximately quarter. up for active strategy, has of in direct also footprint, sales geographies. be portfolio our ordered gone agencies a XX agencies grow one first an XXX from size of and least in define times new the quarter nerve We typically ended important to drive adding to increased the direct team, number contributing our while With part products independent sales the in expanded has sales in sales revenue and of efficiencies algorithms an quarter, we total AxoGen allowing an an committee process, with to in at last been first the active continue agencies months. As able accounts, select our to XXX We account to is our who has converted account create we’ve the accounts the
of is implant revenue products their all of to of full algorithms, repair nerve across to just times the repair. generate expanding six include than ordering four ordering This Our continuum objective account three one least because more of important, an at of accounts treatment is nerve continue surgeons products. surgical the our products our these the
products their the introduction fifth is of and pillar new in growth Our expanded of applications repair.
investments initiatives of repair the pain. expand addressable November our than the to making application nerve foundational surgical nerves. believe unmet In our to launch repair XXXX we product the and peripheral of opportunities in planned could last more treatment to many are address needs and add support products innovate billion broader nerve to market. of We total of application several surgical year, our to portfolio announced repair and to $X we a the help for A
amputation procedures. traumatic patients from discussed, focusing orthopedic we’ve we’re or initially As on injuries, pain resulting experiencing following including
While learning to market, pain in our significant new solutions we’re treat we surge patients. the see in about interest finding still in these early
Before I’m I that repair and in our over an nerve as underserved progress pleased want with long-term confident, expanding building sustainable we against initiatives to drive I strong markets. turn execute large reiterate Pete, capabilities continue across a application. set call I’m growth are the to our strategic to of we to
review call Pete turn I’ll of over Now, a financial the for Pete? highlights. to
